Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | May 23, 2024 | May 24, 2024 |
| LANNETT CO INCLCI · Entity 122287 | Director | September 14, 2022 | September 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date May 23, 2024 · Filed May 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 · Expires 2034-05-23 | Direct | 67,000 |
Reported balance
After 2024-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 67,000 · Balance 67,000 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2: The option is fully vested and exercisable as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F2: The option is fully vested and exercisable as of the date of the grant.
LANNETT CO INC
Report date September 14, 2022 · Filed September 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 93,259 |
Reported balance
After 2022-09-14 transaction · row 1
1 source rowRow 1 · 2022-09-14 · Purchase · Acquired 31,159 · Balance 93,259 F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging between $0.47 and $0.50. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging between $0.47 and $0.50. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2024 Filed May 24, 2024 20:10 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001447028-24-000051 · wk-form4_1716581426.xml · derivative · entry 1 Rewolinski Melissa · CIK 0001780206 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Shares · 67,000 shares Expires 2034-05-23 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date of the grant. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 20:13 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001447028-23-000076 · wk-form4_1689279213.xml · derivative · entry 1 Rewolinski Melissa · CIK 0001780206 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Shares · 110,000 shares Expires 2033-07-12 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on July 12, 2023, the date of the grant. F2 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning one year from the grant date. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 16:52 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon stock | 31,159 | $0.49 | $15,267.91 |
DisclosureSEC source: 0001209191-22-050088 · doc4.xml · nonDerivative · entry 1 Rewolinski Melissa · CIK 0001780206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,259 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging between $0.47 and $0.50. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 16:09 UTC | LANNETT CO INC LCI · Entity 122287 | SaleCommon Stock | 25,340 | $3.18 | $80,581.20 |
DisclosureSEC source: 0001209191-21-055664 · doc4.xml · nonDerivative · entry 1 Rewolinski Melissa · CIK 0001780206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,100 F1 · shares: The sale reported on this Form 4 was made to fund tax obligations associated with previous awards of restricted stock. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.15 to $3.24. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 18:31 UTC | LANNETT CO INC LCI · Entity 122287 | GrantCommon Stock | 56,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054555 · doc4.xml · nonDerivative · entry 1 Rewolinski Melissa · CIK 0001780206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,440 F1 · shares: Represents restricted stock awards that vested in full on August 31, 2021 Read SEC document |
| September 03, 2020 Filed Jun 10, 2021 16:43 UTC | LANNETT CO INC LCI · Entity 122287 | SaleCommon Stock | 14,150 | $5.32 | $75,278.00 |
DisclosureSEC source: 0001209191-21-039505 · doc4.xml · nonDerivative · entry 1 Rewolinski Melissa · CIK 0001780206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,621 F1 · shares: The sale reported on this Form 4 was made, in part, to fund tax obligations with previous awards of restricted stock. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:24 UTC | LANNETT CO INC LCI · Entity 122287 | GrantCommon Stock | 38,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-049399 · doc4.xml · nonDerivative · entry 1 Rewolinski Melissa · CIK 0001780206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,771 F1 · shares: Represents restricted stock awards that vested in full on September 1, 2020 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.